RUNX2 and prostate carcinoma: In order to characterize ongoing bone cell activity in clinical cases of prostate cancer bone metastasis, we selected a set of genes to represent osteoclast activity (ACP5, CTSK, MMP9), osteoblast activity (ALPL, BGLAP, RUNX2) and osteocytes (SOST).